Page last updated: 2024-12-06
isazophos
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 39223 |
| CHEMBL ID | 1879142 |
| CHEBI ID | 82135 |
| SCHEMBL ID | 121685 |
| MeSH ID | M0105280 |
Synonyms (49)
| Synonym |
|---|
| isazophos |
| o-(5-chloro-1-(1-methylethyl)-1h-1,2,4-triazol-3-yl) o,o-diethyl phosphorothioate |
| triumph |
| a-12223 |
| einecs 255-863-8 |
| o-(5-chloro-1-isopropyl-1h-1,2,4-triazol-3-yl) o,o-diethylphosphorothioate |
| cga-12223 |
| ciba 12223 |
| isazofos [bsi:iso] |
| o-5-chloro-1-isopropyl-1h-1,2,4-triazol-3-yl o,o-diethyl phosphorothioate |
| brace |
| hsdb 6684 |
| miral 10 g |
| phosphorothioic acid, o-(5-chloro-1-(1-methylethyl)-1h-1,2,4-triazol-3-yl) o,o-diethyl ester |
| o-(5-chloro-1-isopropyl-1,2,4-triazol-3-yl) o,o-diethyl phosphorothioate |
| ai3-29128 |
| miral |
| isazofos |
| o-(5-chloro-1-isopropyl-1h-1,2,4-triazol-3-yl) o,o-diethyl thiophosphate |
| 42509-80-8 |
| NCGC00168321-01 |
| NCGC00168321-02 |
| C19001 |
| cas-42509-80-8 |
| NCGC00254737-01 |
| dtxsid7034676 , |
| dtxcid5014676 |
| tox21_300833 |
| cf67cg9stq , |
| ccris 8221 |
| unii-cf67cg9stq |
| FT-0630627 |
| isazofos [iso] |
| o-(5-chloro-1-isopropyl-1h-1,2,4-triazol-3-yl) o,o-diethyl phosphorothioate |
| isazofos [mi] |
| phosphorothioic acid o-(5-chloro-1-(1-methylethyl)-1h-1,2,4-triazol-3-yl) o,o-diethyl ester |
| isazofos [hsdb] |
| SCHEMBL121685 |
| CHEBI:82135 , |
| XRHGWAGWAHHFLF-UHFFFAOYSA-N |
| phosphorothioic acid, o-[5-chloro-1-(1-methylethyl)-1h-1,2,4-triazol-3-yl] o,o-diethyl ester |
| o-(5-chloro-1-isopropyl-1h-1,2,4-triazol-3-yl) o,o-diethyl thiophosphate # |
| CHEMBL1879142 |
| isazophos, pestanal(r), analytical standard |
| isazofos 10 microg/ml in isooctane |
| Q27155763 |
| (5-chloro-1-propan-2-yl-1,2,4-triazol-3-yl)oxy-diethoxy-sulfanylidene-lambda5-phosphane |
| STARBLD0009607 |
| CS-0452387 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The tips of the villi were necrotic in the high dosage groups of isazofos- and pyraclofos-treated quail." | ( Risk assessment of the organophosphate pesticides isazofos and pyraclofos using a 21-day dietary toxicity study in Japanese quail. Bae, BK; Cho, SA; Kim, DJ; Park, JH; Seok, SH, 2008) | 0.35 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| organic thiophosphate | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (9)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 89.3584 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 4.5400 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347397; AID1347398; AID1347399 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 12.9484 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 61.1306 | 0.0004 | 17.9460 | 75.1148 | AID1346784 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 5.6629 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 22.5790 | 0.0002 | 29.3054 | 16,493.5996 | AID588514; AID743075 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 22.2125 | 0.0007 | 23.0674 | 1,258.9301 | AID651777; AID743085; AID743122 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 2.4337 | 0.0016 | 28.0151 | 77.1139 | AID1259385 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.64
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.64) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (11.11%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||